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Background/aim: Verruca vulgaris is a benign disease characterized with papillomas on the skin and mucosa. The aim of this study was
to investigate the serum levels of coenzyme Q10, MDA, and zinc as well as the lipid profile of verruca vulgaris patients and examine the
relationship between these parameters and clinical manifestations of the disease.
Materials and methods: The study included 49 verruca vulgaris patients (mean age: 32.01 ± 14.20 years; 22 males, 27 females) and 40
healthy volunteers (mean age: 31.63 ± 8.98 years; 21 males and 19 females). Coenzyme Q10 levels were assessed by using an enzymelinked immunosorbent assay. Serum MDA levels were measured spectrophotometrically. Zinc levels were measured using a Perkin
Elmer AAnalyst 800 atomic absorption spectrometer with a deuterium background correction and additional standard techniques.
Results: The coenzyme Q10 levels were found to be higher in the verruca vulgaris group compared to the healthy volunteers. However,
this increase was not statistically significant (P = 0.195). Zinc levels were significantly lower in the verruca vulgaris group compared to
the healthy volunteers (P = 0.002). In the patient group, MDA levels and HDL levels were significantly higher compared to the healthy
volunteers (P = 0.023 and P = 0.004, respectively). Additionally, there was no statistically significant difference between the groups in
the CoQ10/Total cholesterol ratio (P = 0.433).
Conclusion: Reduced serum zinc levels and increase of oxidative stress in verruca vulgaris may be a factor responsible for development
of verruca vulgaris.
Key words: Coenzyme Q10, verruca, zinc, MDA

1. Introduction
Verruca vulgaris is a benign disease characterized with
papillomas on the skin and mucosa that is caused by
infection with the human papilloma virus (HPV). The
warts can be transmitted by direct contact with people or
through use of common items with an infected individual.
Various factors such as the strength of the skin barrier, viral
titre and immunological responses of the patients play a
role in the infection. The virus infects the epithelial basal
cells and this situation triggers proliferation of epithelial
basal cells [1,2]. Although various treatment options for
verruca exist, it is occasionally resistant to treatment or may
resolve spontaneously due to a natural immune response.
Long-term persistence, multiple treatment necessities and
recurrence after treatment of the verruca lesions generally
suggest the presence of some immunological impairment
in virus infected individuals.
Zinc is an essential element and plays an important
role in many basic physiological functions in the body,
particularly in the function of the adaptive and innate

immune systems [3]. Zinc deficiency can lead to a
suppression of the immune response, decrease in the
number of T, B and natural (NK) cells and reduced
chemotactic responses of neutrophils, monocytes and
macrophages. Thus, zinc deficiency may be associated
with a tendency to enhance bacterial, fungal and viral
infections [4].
Various studies have shown that oxidative stress
increases in patients with verruca vulgaris. Reactive oxygen
species (ROS) that are generated during oxidative stress
may lead to the formation of toxic oxidation products from
lipids such as malondialdehyde (MDA), which may play a
role in the etiopathogenesis of verruca vulgaris and have an
effect on the chronicity of the disease [5]. Coenzyme Q10
is a compound of the ubiquinone family that is synthesized
in humans and in all animals. It prevents the onset of lipid
peroxidation and damage of biomolecules by interfering
with ROS formation. Various other functions of coenzyme
Q10 include stabilization of the cell membrane, regulation
of cell signalling, gene expression, cell proliferation and
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apoptosis [6]. Coenzyme Q10 has gained popularity as a
dietary supplement in recent years [7,8].
The aim of this study was to investigate the serum levels
of coenzyme Q10, MDA, and zinc as well as the lipid profile
of verruca vulgaris patients and examine the relationship
between these parameters and clinical manifestations of
the disease.
2. Materials and methods
The ethical approval for this study was obtained from
Süleyman Demirel University, Faculty of Medicine
Ethics Committee (Number: 119). Informed consent
was obtained from all participants before the study was
commenced.
2.1. Selection of cases for the study
The study included 49 verruca vulgaris patients (mean age:
32.01 ± 14.20 years; 22 males, 27 females) and 40 healthy
volunteers (mean age: 31.63 ± 8.98 years; 21 males, 19
females) from the Süleyman Demirel University Research
Hospital, Department of Dermatology and Venereology.
Verruca vulgaris was diagnosed with clinical assessment.
Patients with dermatological diseases other than verruca
vulgaris, cigarette/alcohol use, systemic disease such
as cardiac, renal or hepatic diseases, diabetes mellitus,
infectious diseases, malignancy, inflammatory rheumatoid
diseases, pregnancy, or any history of medication within
the last 3 months were excluded from the study. The sex,
age, locations of lesions, treatment history, and disease
duration of the patients were recorded. Dermatological
examination was performed by a single dermatologist.
2.2. Biochemical tests
Venous blood samples were collected from patients and
controlled after an overnight fasting period and were
centrifuged at 3000 rpm for 10 min. The serum was
separated into eppendorf tubes for analysis and kept at –80
°C until analysis. Coenzyme Q10 levels were assessed by
using an enzyme-linked immunosorbent assay kit (Human
CoQ10-ELISA kit/Shanghai Sunred Biological Technology
Co, Ltd, Shanghai, China) and were expressed in ng/mL.
Total cholesterol levels were measured by an enzymatic
method on a Beckman Coulter AU5800 (USA) clinical
chemistry analyser and expressed in mg/dL. Serum MDA
levels were measured spectrophotometrically according
to the double heating method of Draper and Hadley
and expressed in µmol/L. Zinc levels were measured
using a Perkin Elmer AAnalyst 800 atomic absorption
spectrometer (USA) with a deuterium background
correction and additional standard techniques [9,10]. Zinc
levels were expressed in µg/dL.
2.3. Statistical analysis
All data in the study were analysed with SPSS for
Windows Version 22.0 (IBM Corp., Armonk, NY, USA).
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Normality of variables was tested with the Kolmogorov–
Smirnov test. Descriptive analyses are presented as
mean ± standard deviation (SD) or median (minimummaximum). The chi-square test was performed for
qualitative variables. Student’s t-test was used to compare
normally distributed variables and Mann–Whitney U test
was used for nonnormal distributed variables. Spearman
test was used for calculating correlation coefficients and
their significance. A P value of <0.05 was considered as
significant.
3. Results
There were no statistically significant differences between
the patient and control groups in terms of age and sex (P
> 0.05 for all comparisons). Descriptive variables, clinical
and laboratory characteristics of the study groups are
shown in Table 1. The mean duration of verruca vulgaris
in the patients ranged from 1–120 months (19.35 ±
28.82). The lesion was located at the genital area in 18
patients (36.7%) and in a nongenital area (hand, foot,
face, trunk) in 31 patients (63.3%). The coenzyme Q10
levels were found to be higher in the verruca vulgaris
group compared to the healthy volunteers. However, this
increase was not statistically significant (P = 0.195). Zinc
levels were significantly lower in the verruca vulgaris
group compared to the healthy volunteers (P = 0.002).
In the patient group, MDA levels and HDL levels were
significantly higher compared to the healthy volunteers
(P = 0.023 and P = 0.004, respectively). There was no
statistically significant difference between the groups in
serum total cholesterol, triglyceride, LDL, VLDL levels
(P > 0.05 for all). Additionally, there was no statistically
significant difference between the groups in the CoQ10/
total cholesterol ratio (P = 0.433). Thirty-eight of the
patients (77.6 %) were treated with cryotherapy and the
remaining 6 (12.2%) were provided with other treatment
options (Table 1).
Number of verruca lesions was significantly higher in
patients with genital warts compared to patients without
genital warts (P = 0.029). However, the duration of verruca,
number of lesions, zinc, MDA, coenzyme Q10 levels, lipid
profile as well as CoQ10/total cholesterol ratio were similar
in patients with genital and patients with nongenital warts
(Table 2).
Age and LDL levels were found to be negatively
correlated with coenzyme Q10 levels. Total cholesterol
and Coenzyme Q10/total cholesterol ratio were positively
correlated with the coenzyme Q10 levels. Number of warts
were positively correlated with zinc levels (Table 3).
4. Discussion
In this study, coenzyme Q10 and MDA levels were found
to be higher in patients with verruca vulgaris while the
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Table 1. Descriptives, clinical and laboratory characteristics of the cases and controls.
Cases (n: 49)

Controls (n: 40)

P

27 (55.1 %)
22 (44.9 %)

19 (47.5%)
21 (52.5%)

0.475*

Age

32.01 ± 14.20,
26.00 (18–65)

31.63 ± 8.98,
32.00 (20–53)

0.866**
0.270***

Duration of verruca, month, mean ± SD

19.35 ± 28.82 (1–120)

-

Patients with genital verruca, n(%)

18 (36.7)

-

Patients with nongenital (hand, foot, face, trunk) verruca,n (%)

31 (63.3)

-

Number of verrucas, mean ± SD (min–max)

9.22 ± 14.88 (1–100)

-

Treatment
Cryotherapy, n (%)
Others (imiquimod, salicylic acid, and 5-fluorouracil) n (%)

38 (77.6 %)
6 (12.2 %)

Zinc, median (min–max)

77.73 (52.5–113.9)

91.50 (57.4–215.9)

0.002***

Co enzyme Q, median (min–max)

35.98 (8.2–271.7)

29.82 (2.2–187.6)

0.195***

MDA, median (min–max)

4.56 (3.86–6.92)

4.42 (1.46–17.95)

0.023***

Total cholesterol, median (min-max)

172.12 (118.87–381.70)

167.49 (106.42–271.19)

0.177***

Triglyceride, median (min–max)

90.26(27.78–392.57)

131.41 (30.28–637.55)

0.229***

LDL, median (min–max)

105.30 (56.0–258.13)

98.36 (0–194.38)

0.117***

VLDL, median (min–max)

18.0 (6.0–79.0)

26.50 (6–128)

0.246***

HDL, mean ± SD

48.79 ± 12.58

41.83 ± 9.31

0.004**

CoQ10/T.chol, median (min-max)

0.17 (0.031–1.63)

0.18 (0.014–1.31)

0.433***

Sex
Female, n (%)
Male, n (%)

*P value was determined by chi-Square test
**P value determined by Independent samples t-test
***P value was determined Mann–Whitney U test

serum zinc levels were significantly lower. This suggests
that the presence of underlying oxidative stress in verruca
vulgaris patients may affect the immunological response
of these patients.
Zinc is an essential element that plays an important role
in many biological processes in addition to its antioxidant
effect [11,12]. Studies have shown that the antioxidant
effect of zinc is achieved by inducing the activity of
Metallothionein 5 (MT5). Metallothioneins (MT) are
cellular proteins rich in zinc, copper and cysteine. These
proteins are expressed in various tissues and protect against
oxidative stress by inducing apoptosis. The antioxidant
effect of MTs is mainly due to the presence of zinc in
its structure. MTs act as free oxygen radical scavengers
that inhibit DNA damage and lipid peroxidation. The
sulfhydryl groups in MTs react with hydroxyl radicals and
zinc is released to the environment. This results in a 300fold greater binding of the sulfhydryl groups to free oxygen

radicals, thereby reducing oxidative stress. Consequently,
oxidative stress increases with zinc deficiency [11,13].
Clinical studies have indicated that zinc sulphate
has therapeutic value. It was reported that intralesional
application of 2% zinc sulphate in patients with verruca
was efficacious and suggested that zinc could be among
the treatment options [3,14]. In another study, oral zinc
sulphate was started at 10 mg/kg dose in treatment resistant
verruca patients; zinc was found to be highly effective in
the treatment of resistant verruca compared to the control
group [12]. Seareh et al. [15] reported that the combination
of zinc sulphate with conventional therapies was effective
as a treatment option and could reduce the relapse rate.
In a randomized, double-blind, placebo-controlled study
zinc sulphate was administered to 83 patients in addition
to cryotherapy; however, no significant difference was
observed in the outcome when compared to the placebo
control group [16]. Raza et al. [17] reported low serum
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Table 2: Descriptives, clinical and laboratory characteristics of the patients with genital and nongenital verruca vulgaris.
Patients with genital verruca
(n: 18)

Patients with nongenital verruca
(n: 31)

P

Sex
Female, n (%)
Male, n (%)

5 (27.8%)
13 (72.2%)

23 (74.2%)
8 (25.8 %)

0.002*

Age, mean ± SD (median)

34.50 (18–64)

25 (18–65)

0.092**

Duration of verruca (month), median (min–max)

3.00 (1.00–120)

12.00 (1.00–120)

0.103**

Number of verrucas, median (min–max)
Treatment
Cryotherapy, n (%)
Others (imiquimod, salicylic acid and
5-fluorouracil) n (%)
Zinc, median (min–max)

10 (1–100)

4.00(1.00–23.00)

0.029**

15 (83.3%)
3 (16.7%)

28 (90.3%)
3 (9.7%)

0.479*

80.34 (61.3–113.9)

77. 59 ± 11.94 (76.71)

0.455**

Co enzyme Q, median (min–max)

37.73 (8.2–208.5)

42.01 (8.60–271.70)

0.455**

MDA, median (min–max)

4.65(4.21–6.84-6.92)

4.48 (3.86–6.92)

0.437**

Total cholesterol, median (min–max)

178.81 (118.87–329.36)

172.12 (128.71–381.70)

0.917**

Triglyceride, median (min–max)

125.81(37.85–283.99)

86.36 (27.78–392.57)

0.213**

LDL, median (min–max)

109.97(56.0–255.91)

105.30 (69.87–258.13)

0.772**

VLDL, median (min–max)

25.50 (8.0–57.0)

17.00 (6.00–79.00)

0.249**

HDL, median (min–max)

42.29 (28.00–70.13)

50.04 (30.62–83.08)

0.237**

CoQ10/T.chol, median (min–max)

0.162(0.031–1.57)

0.22(0.40–1.63)

0.520**

*P value was determined by chi-Square test
**P value was determined Mann–Whitney U test
Table 3 Correlation coefficients between coenzyme, zinc and age, number of
verrucas (Spearman).
Coenzyme Q
(r)

Zinc
(r)

MDA
(r)

Age
(r)

Age

–.402**

.016

.239

≈1

Number of verrucas

–.103

.297*

.0.008

–.032

Total cholesterol

.377**

.213

.450**

–.496***

Triglyceride

–.213

.058

.364**

.274

LDL

–.428**

.216

.388**

.571***

VLDL

–.218

.055

.366*

.287*

HDL

.204

.087

–.014

–.183

CoQ10/T.chol

.960***

.168

–.254

–.472**

Number of verrucas

–.103

.297*

.008

–.032

*P < 0.05 **P < 0.01 ***P < 0.001

zinc levels in persistent verruca vulgaris patients with more
than 10 warts and disease duration of more than 6 months
and suggested that zinc deficiency might be involved in the
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resistant cases. In the current study, patients with verruca
vulgaris were found to have significantly decreased serum
zinc levels compared to the control group. However, no
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correlation was found between the location of the lesions
(genital versus nongenital), duration of the disease,
and serum zinc levels. These data support the role of
zinc deficiency and resulting immunodeficiency in the
etiopathogenesis of the disease rather than the duration
of the disease. Interestingly, we observed a significant
positive correlation between the serum zinc levels and
number of warts. It is possible that a dysregulation in the
transition of zinc from the serum to the tissue and thereby
reduced zinc levels in the tissue could result in impaired
antioxidant and immune functions leading to an increase
in the number of lesions.
Reactive oxygen radicals are produced during normal
tissue metabolism that are destroyed by an endogenous
antioxidant system. If the antioxidant mechanism is
perturbed, the resulting ROS can cause deterioration
of cell functions due to the damage of lipids, DNA and
proteins. ROS is also known to suppress T cell signalling,
activation and proliferation [18].
The relationship between verruca and oxidative stress
is well-established [5,19]. A number of immunological
factors can be affected by oxidative stress; which, in
turn can further exacerbate oxidative stress. MDA is a
marker of oxidative stress indicating ROS induced lipid
peroxidation. Arıcan et al. [5] examined that levels of
MDA and the antioxidant enzymes catalase (CAT), and
superoxide dismutase (SOD) in lesion and nonlesion skin
samples of 36 patients with verruca vulgaris. The skin
samples obtained from verruca lesions were found to have
higher levels of MDA and lower levels of SOD compared
to the nonlesion areas. These authors concluded that
oxidative stress may play a role in the etiopathogenesis
of verruca vulgaris. On the other hand, Çokluk et al. [19]
evaluated serum CAT, MDA, paraoxonase and GSH-Px
levels in 32 patients with genital warts and reported no
significant differences with the control group.
In the current study, corroborating the data reported
by Arıcan et al., we observed significantly higher serum
MDA levels in the verruca patients compared to the
control group. Increased oxidative stress in these patients
was likely to compromise not only the immune response,
but also the affect the inflammatory process.
Coenzyme Q10 is found in all tissues in humans
and plays a central role in the mitochondrial respiratory
system in the synthesis of ATP. Coenzyme Q10 also acts
as an antioxidant by interacting with oxygen-induced
radicals, thereby preventing the onset of lipid peroxidation
and damage of biomolecules. Coenzyme Q10 has also
been shown to play a role in cell membrane stability, cell
signalling, gene expression, cell growth, and apoptosis
[8,20]. In addition, coenzyme Q10 is known to protect
membrane phospholipids and low-density lipoproteins
from peroxidation (20). A balance between oxidant

and antioxidant levels was thought to contribute to the
spontaneous regression of verruca lesions [21].
Coenzyme Q10 is transported with cholesterol and
lipoproteins and its levels can therefore be correlated
with plasma cholesterol concentration. So, the coenzyme
Q10 to total cholesterol ratio has also been reported in
the literature [22]. In the current study, both coenzyme
Q10 and coenzyme Q10/cholesterol ratio were evaluated.
Coenzyme Q10 level was high in the patient group
compared to the control group. This suggests the likely
presence of a feedback mechanism whereby enhanced
lipid peroxidation and increased levels of MDA could
lead to a greater requirement of antioxidant functions and
higher amounts of coenzyme Q10. It also suggests that this
molecule, which is affected by lipid parameters, may also
affect other currently unknown regulatory mechanisms.
In addition, no significant difference was observed in the
coenzyme Q10 levels, coenzyme Q10/total cholesterol
ratio and lipid profiles between the patient and control
groups and between the genital and nongenital patient
groups. Total cholesterol levels were found to be higher
in the patient group compared to controls; however, this
difference was not statistically significant. This suggests
that oxidative stress is more likely to affect the pathogenesis
of verruca vulgaris rather than its location. Moreover,
although the coenzyme Q10 levels were found to be higher
in the patient group, these patients also showed higher
total cholesterol levels than the control groups, which
resulted in no significant change in the coenzyme Q10/
total cholesterol ratio.
The low patient number and the fact that the markers
were not simultaneously evaluated in the serum and tissues
are the limiting aspects of the current study.
In conclusion, the serum levels of zinc in verruca
vulgaris patients were lower compared to the healthy
control group; additionally, this decrease was significant.
Reduced serum zinc and increase of oxidative stress
in verruca vulgaris may be a factor responsible for the
development of verruca vulgaris. Thus, more studies
with bigger sample sizes are needed to better evaluate the
relationship between oxidative stress mechanisms and
the immune system in the etiopathogenesis of verruca
vulgaris.
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